These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1226 related articles for article (PubMed ID: 15309512)

  • 1. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
    J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Which role do new therapeutic options play in palliative care of colorectal cancer?].
    Verbeek W; Graeven U
    Internist (Berl); 2005 Dec; 46(12):1339-46. PubMed ID: 16228155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of new agents in the treatment of colorectal cancer.
    Folprecht G; Köhne CH
    Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting vascular endothelial growth factor in colorectal cancer.
    Berlin JD
    Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):13-5. PubMed ID: 12199627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biotherapy in colorectal cancer].
    Des Guetz G
    J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of targeted therapy in the treatment of colorectal cancer.
    Goldberg RM; Hurwitz HI; Fuchs CS
    Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
    Eng C
    Oncologist; 2010; 15(1):73-84. PubMed ID: 20067946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of bevacizumab as first-line therapy for colon cancer.
    Marshall J
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
    Vincenzi B; Santini D; Russo A; Gavasci M; Battistoni F; Dicuonzo G; Rocci L; Rosaria VM; Gebbia N; Tonini G
    Pharmacogenomics; 2007 Apr; 8(4):319-27. PubMed ID: 17391070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.